Search
latanoprost/netarsudil (Rocklatan)
FDA approved April 2019.
latanoprost 0.005% / netarsudil 0.02%
Indications:
- open-angle glaucoma
Dosage:
- one drop in affected eye(s) QHS
Clinical significance:
- may be more effective in lowering intraocular pressure than either agent alone
Mechanism of action:
- see latanoprost & netarsudil
General
pharmacologic combination
Database Correlations
PUBCHEM cid=118984471
References
PubChem: 118984471
Components
latanoprost (Xalatan)
netarsudil (Rhopressa)